Cystic Fibrosis Pipeline Insight

DelveInsight’s, “Cystic Fibrosis Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cystic Fibrosis Understanding

Cystic Fibrosis Overview

Cystic fibrosis (CF) is a rare, inherited, life-shortening genetic disorder that primarily affects the lungs, digestive system, and other organs. It is caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which regulates the movement of salt and water across cell membranes. Defective CFTR protein function results in the production of thick, sticky mucus that accumulates in various organs, leading to chronic infections, inflammation, and progressive organ damage. CF is inherited in an autosomal recessive pattern, meaning an individual must inherit two defective copies of the CFTR gene to develop the disease.

The respiratory system is the most commonly affected organ system in CF. Thick mucus obstructs the airways, creating an environment that promotes recurrent bacterial infections and chronic inflammation. Over time, repeated infections can lead to bronchiectasis, declining lung function, respiratory failure, and other pulmonary complications. Common respiratory symptoms include a persistent cough with thick mucus, wheezing, shortness of breath, recurrent chest infections, chronic sinusitis, and nasal polyps.
Cystic fibrosis also significantly affects the digestive system. Thick secretions can block the ducts of the pancreas, preventing digestive enzymes from reaching the intestines and impairing nutrient absorption. As a result, individuals may experience poor weight gain, malnutrition, greasy and bulky stools (steatorrhea), abdominal pain, constipation, and delayed growth. In infants, meconium ileus, a blockage of the intestine caused by thick stool, may be one of the earliest signs of the disease.

Additional signs and symptoms of CF may include salty-tasting skin due to elevated chloride levels in sweat, fatigue, delayed puberty, reduced fertility, and complications affecting the liver, bones, and endocrine system. Many patients develop CF-related diabetes as they age. The severity and progression of symptoms vary widely depending on the specific CFTR mutation and the extent of organ involvement. Advances in diagnosis and treatment, including CFTR modulator therapies, airway clearance techniques, antibiotics, and nutritional support, have significantly improved outcomes for people with CF. Early diagnosis through newborn screening and comprehensive multidisciplinary care can help manage symptoms, reduce complications, and improve both life expectancy and quality of life.
 
"Cystic Fibrosis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystic Fibrosis pipeline landscape is provided which includes the disease overview and Cystic Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Cystic Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Cystic Fibrosis Pipeline Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cystic Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Cystic Fibrosis.

Cystic Fibrosis Emerging Drugs Analysis

This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and 
Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cystic Fibrosis Emerging Drugs

AP-PA02: Armata Pharmaceuticals

AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an emphasis on patients with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). Phages that comprise AP-PA02 were selected with desired attributes for a product candidate targeting P. aeruginosa lung infections. AP-PA02 is comprised of a cocktail of natural P. aeruginosa phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility and cooperativity, and further characterized by being highly potent and having a broad host range. Currently, the drug is in the Phase II stage of its development for the treatment of Cystic Fibrosis.

BI 3720931: Boehringer Ingelheim

BI 3720931 is an investigational therapy being developed by Boehringer Ingelheim for the treatment of cystic fibrosis (CF). It is a next-generation CFTR modulator designed to restore the function of defective CFTR protein, thereby improving chloride transport and reducing the buildup of thick mucus in the lungs and other organs. The therapy is being evaluated as part of Boehringer Ingelheim's efforts to develop mutation-targeted treatments for CF and may be used in combination regimens to enhance clinical outcomes. BI 3720931 remains in clinical development, with studies assessing its safety, pharmacokinetics, and efficacy in patients with cystic fibrosis. Currently, the drug is in the Phase I/II stage of its development for the treatment of Cystic Fibrosis.

KB407: Krystal Biotech, Inc. 

KB407 is an investigational inhaled gene therapy being developed by Krystal Biotech, Inc. for the treatment of cystic fibrosis (CF). The therapy utilizes the company's proprietary engineered herpes simplex virus-1 (HSV-1) vector platform to deliver a functional copy of the CFTR gene directly to airway epithelial cells. KB407 is designed to address the underlying genetic cause of CF regardless of the patient's specific CFTR mutation. Early clinical studies have demonstrated successful gene delivery and a favorable safety profile, supporting its ongoing development as a potential mutation-agnostic treatment for cystic fibrosis. Currently the drug is in Phase I stage of its development for Cystic Fibrosis.

Further product details are provided in the report……..

Cystic Fibrosis Drug Therapeutic Assessment

This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Cystic Fibrosis
• There are approx.50+ key companies which are developing the therapies for Cystic Fibrosis. The companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. Phase II include, Armata Pharmaceuticals.

Cystic Fibrosis Clinical Trial Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cystic Fibrosis Drug Route of Administration

Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Cystic Fibrosis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Cystic Fibrosis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cystic Fibrosis:Clinical Trial Activities

The Cystic Fibrosis Pipeline report provides insights into different Cystic Fibrosis Clinical Trial within Phase III, II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs. 

Cystic Fibrosis Pipeline Development Activities

The Cystic Fibrosis Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.

Cystic Fibrosis Report Insights

• Cystic Fibrosis Pipeline Analysis
• Cystic Fibrosis Therapeutic Assessment
• Cystic Fibrosis Unmet Needs
• Impact of Cystic Fibrosis Drugs

Cystic Fibrosis Report Assessment

• Cystic Fibrosis Pipeline Product Profiles
• Cystic Fibrosis Therapeutic Assessment
• Cystic Fibrosis Pipeline Assessment
• Cystic Fibrosis Inactive drugs assessment
• Cystic Fibrosis Market Unmet Needs

Key Questions Answered in the Cystic Fibrosis Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cystic Fibrosis drugs?
• How many Cystic Fibrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cystic Fibrosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cystic Fibrosis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Cystic Fibrosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Cystic Fibrosis Key Players

• Armata Pharmaceuticals
• Boehringer Ingelheim
• Krystal Biotech, Inc.
• Vertex Pharmaceuticals Incorporated
• ReCode Therapeutics

Cystic Fibrosis Key Products

• AP-PA02
• BI 3720931
• KB407
• VX-121/TEZ/D-IVA
• RCT2100